Danaher Corporation's first-quarter 2026 earnings report carried a signal that will matter to anyone running or supplying a bioprocessing lab: equipment orders grew more than 30% year over year in Q1, marking the first quarter of positive order growth in nearly two years. For lab managers who have been watching the bioprocessing sector absorb inventory corrections and capital freezes since 2023, that number suggests the cycle may finally be turning.
It wasn't the only relevant data point from the call. New product introductions from Cytiva and Beckman Coulter, a candid acknowledgment of tariff pressures, a significant pending acquisition, and a clear-eyed view of where academic and government labs stand all deserve attention from lab managers tracking the direction of their sector.
Bioprocessing Equipment Orders Surge — What It Means for Biopharma Labs
The standout data point of the earnings call came from the Biotechnology segment, which houses Cytiva, Danaher's life sciences and bioprocessing business. Core revenue grew 7% in Q1, with bioprocessing consumables posting high single-digit growth driven by robust demand for commercialized therapies. Equipment revenue declined modestly on a sales basis — but the order book told a different story.
"Orders growth of more than 30%, marking the first quarter of year-over-year equipment order growth in nearly two years," Blair told analysts on the call. He described the trend as the beginning of a multi-year investment cycle, with brownfield expansions already entering the funnel and larger greenfield projects expected to follow.
Reshoring was explicitly cited as a driver. Blair noted that Danaher is seeing "increased dialogue, active funnels, and even some orders for brownfield expansions related to reshoring" — directly paralleling the manufacturing capacity rebuild narrative that Thermo Fisher also flagged in its own call. For labs embedded in biopharma manufacturing supply chains, this is a meaningful indicator of where capital is going to flow over the next several years.
On the product side, Cytiva launched Fibro dT, a next-generation mRNA purification platform designed to improve manufacturing speed and efficiency. By eliminating the diffusion limitations of traditional purification methods, Fibro dT reduces processing time, increases yield, and lowers material usage — a meaningful advance for labs scaling mRNA-based therapies. Cytiva is also showcasing a next-generation Automated Perfusion System (APS) at INTERPHEX this week — a tangential flow filtration platform targeting process intensification challenges, including product loss, filter clogging, and scalability.
Lab Management Certificate
The Lab Management certificate is more than training—it’s a professional advantage.
Gain critical skills and IACET-approved CEUs that make a measurable difference.
Blair's broader framing on bioprocessing was direct: "Monoclonal antibody production remains robust and is expected to continue growing at historical or better rates, driven by new molecules, biosimilars, and increased utilization of existing therapies." He added that equipment investment has been "relatively muted" during the recovery period, which he said "creates a growing need for incremental capacity in the coming years."
Diagnostics: Strong Outside China, Pressure Within
For clinical and diagnostic lab managers, the Diagnostics segment picture was more nuanced. Core revenue declined 4% overall, driven primarily by two factors: a lighter-than-normal respiratory season at Cepheid, which saw respiratory revenue fall roughly 25% year over year, and continued pricing headwinds in China from volume-based procurement and reimbursement policy changes.
But the underlying non-respiratory picture was considerably more positive. Blair highlighted that Cepheid's non-respiratory test menu grew mid-teens in Q1, including 20% growth in sexual health and hospital-acquired infection assays. The recently cleared Xpert GI Panel is driving strong early customer interest and supports what Blair described as Cepheid's expanding multiplexing strategy — offering labs broader infectious disease testing capability from a single platform.
Interested in lab leadership?
Beckman Coulter Diagnostics delivered mid-single-digit growth outside China, led by immunoassay reagents and instrumentation. Notably, the DxI 9000 Immunoassay Analyzer received FDA clearance of the HBc IgM assay for acute hepatitis B during the quarter. Blair called the clearance significant: "With this clearance, nearly all core blood virus assays for the DxI 9000 are now cleared in both the U.S. and the European Union. This closes a historical gap in Beckman's immunoassay test menu and positions Beckman to accelerate new placements, customer wins, and growth as the DxI 9000 rollout continues."
DxI 9000 Immunoassay Analyzer | Beckman Coulter Diagnostics
For lab managers evaluating clinical chemistry and immunoassay platforms, the DxI 9000's expanded menu and the Xpert GI Panel clearance are both worth noting as near-term procurement considerations.
AI and Lab Automation: Beckman Coulter Partners with Automata
On the AI and automation front, Danaher announced that Beckman Coulter Life Sciences has entered a strategic partnership with Automata, combining Beckman's liquid handling, genomic, and cell analysis technologies with Automata's AI-ready automation platform. Blair described the collaboration as designed to "empower scientists with AI-driven tools in automated workflows to improve throughput, workflow reliability, and data integrity in an increasingly autonomous research environment."
It's a direction Lab Manager has been tracking closely. The trend toward agentic AI embedded in laboratory workflows and automation platforms that connect instruments, data systems, and analytical pipelines is accelerating across the industry — and this partnership is a concrete example of how established instrument makers are building toward that future through collaboration rather than building entirely in-house.
Blair's comments on AI were characteristically direct: "We think AI is going to be a growth accelerator for the pharma and biotech industry, both in the near and in the long term."
Tariffs and Supply Chain: Managing Exposure Proactively
Like Thermo Fisher's CFO a day later, Danaher's CFO Matt McGrew discussed tariff and inflationary pressures candidly. Blair framed the company's approach as proactive: "We remain focused on controlling what we can control, including leveraging the Danaher Business System to proactively manage our supply chain and mitigate inflationary pressures while continuing to invest for the long term."
Danaher's exposure is limited relative to some peers — Blair noted limited direct revenue or supply chain exposure to the Middle East conflict — but the company is nonetheless actively managing cost structure and productivity to offset the broader inflationary environment. For lab managers, this is consistent with what other major suppliers are signaling: supply chain stability remains a management priority, and cost pressures on consumables and logistics are real and ongoing. Lab Manager has covered both tariff mitigation strategies and how to build a more resilient lab supply chain for lab leaders navigating this environment.
Academic and Government Labs: Stable but Still Muted
Blair's characterization of the academic and government market closely echoed what Thermo Fisher reported the following day. In Life Sciences Instruments, core revenue declined in the low single digits, driven primarily by weakness among North American academic research customers. Blair described demand as "muted" but noted early signs of momentum building in the order book and "some pockets of improved order and funnel activity" at smaller biotech and academic customers.
Aldevron grew in the quarter, driven by improved commercial execution and a recovering biotech funding environment. Abcam also saw early improvement in academic research consumables. Blair described Abcam's recent performance as evidence that the Danaher Business System's commercial and operational discipline is gaining traction since the acquisition, with margin expansion following.
For labs in academic and government settings, the picture from two consecutive earnings calls at two of the largest life science companies is consistent: conditions are stable to slightly improving, but a return to normalized demand is not yet assumed in any company's guidance.
The Masimo Acquisition: What It Signals
Announced in February and discussed at length on the call, Danaher's pending acquisition of Masimo — a leader in pulse oximetry and patient monitoring in acute care settings — is notable for what it reveals about where Danaher is positioning its Diagnostics business. Blair explicitly compared the Masimo opportunity to the Radiometer acquisition, describing both as "mission-critical" acute care diagnostics plays where Danaher's operational system can drive performance improvement over time.
The deal is expected to be accretive to adjusted EPS in the first full year post-close, with $125 million in cost synergies and $50 million in revenue synergies projected by year five. The transaction remains subject to regulatory approval. For clinical lab managers, the strategic direction is worth tracking: Danaher is building a deeper acute care diagnostics footprint, expanding beyond the traditional lab into point-of-care monitoring environments.
What's Ahead
Danaher raised the high end of its full-year adjusted EPS guidance to a range of $8.35–$8.55 and maintained its full-year core revenue growth outlook of 3%–6%. For Q2, the company expects low-single-digit core revenue growth, with bioprocessing expected to continue growing at mid-single-digit rates and Life Sciences expected to hold roughly flat.
The multi-year bioprocessing equipment cycle Blair described — brownfield now, greenfield to follow — sets a clear directional signal for biopharma labs making capital planning decisions for the next 18–36 months. For those evaluating the total cost of ownership on new bioprocessing infrastructure against a backdrop of improving demand fundamentals, the timing context from this call is useful data.
Sources: Danaher Corporation Q1 2026 Earnings Press Release, April 21, 2026, and Q1 2026 Earnings Conference Call transcript. Quotes sourced from the published earnings call transcript.
